Bendamustine/polatuzumab-vedotin/rituximabVarious toxicities: 5 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1889卷 / 1期

关键词：

D O I：

10.1007/s40278-022-08763-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：84 / 84

相关论文

共 50 条

[1] Bendamustine/polatuzumab-vedotin/rituximabVarious toxicities: 3 case reports
[J]. Reactions Weekly, 2022, 1893 (1) : 73 - 73
[2] Bendamustine/polatuzumab-vedotin/rituximabVarious toxicities and compassionate use: 7 case reports
[J]. Reactions Weekly, 2022, 1927 (1) : 130 - 130
[3] Bendamustine/polatuzumab vedotin/rituximabVarious toxicities: 5 case reports
[J]. Reactions Weekly, 2022, 1914 (1) : 125 - 125
[4] Bendamustine/Polatuzumab-vedotin/RituximabLack of efficacy
[J]. Reactions Weekly, 2024, 2009 (1) : 113 - 113
[5] Bendamustine/polatuzumab-vedotin/rituximabPeripheral neuropathy and lack of efficacy: 4 case reports
[J]. Reactions Weekly, 2022, 1921 (1) : 64 - 64
[6] Bendamustine/rituximabVarious toxicities: 5 case reports
[J]. Reactions Weekly, 2015, 1547 (1) : 52 - 52
[7] Bendamustine/rituximabVarious toxicities: 5 case reports
[J]. Reactions Weekly, 2019, 1744 (1) : 64 - 64
[8] Bendamustine/rituximabVarious toxicities: 5 case reports
[J]. Reactions Weekly, 2015, 1540 (1) : 60 - 60
[9] Bendamustine/polatuzumab-vedotin/rituximabMucormycosis and severe COVID-19: 2 case reports
[J]. Reactions Weekly, 2023, 1941 (1) : 100 - 100
[10] Bendamustine/polatuzumab-vedotin/rituximabCytokine release syndrome
[J]. Reactions Weekly, 2024, 1998 (1) : 114 - 114

← 1 2 3 4 5 →